N

NRX Pharmaceuticals
D

NRXP

1.25500
USD
0.04
(2.87%)
مغلق
حجم التداول
273
الربح لكل سهم
-3
العائد الربحي
-
P/E
-1
حجم السوق
15,178,088
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    AGIO
    -1.645
    (-2.97%)
    53.810 USD
    B
    BLUE
    -0.04270
    (-11.74%)
    0.32090 USD
    C
    CRSP
    0.360
    (0.77%)
    47.280 USD
    E
    EDIT
    -0.11500
    (-4.14%)
    2.66500 USD
    I
    INCY
    -1.840
    (-2.37%)
    75.890 USD
    M
    MRTX
    0
    (0%)
    0.000000 USD
    R
    RARE
    -2.865
    (-6.02%)
    44.745 USD
    S
    SGMO
    -0.10000
    (-4.67%)
    2.04000 USD
    VRTX
    VRTX
    -18.53
    (-3.83%)
    450.72 USD
    المزيد
الأخبار

العنوان: NRX Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.